Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

Recruiting now · Phase 2

Conditions studied: Lung Cancer

In brief

This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.

Key facts

Study ID

NCT05849129

Run by

The Canadian College of Naturopathic Medicine

People needed

90

Starts

2024-10-01

Expected to finish

2031-10-01

Last updated by the study team

2026-01-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer
• Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy

You may not qualify if…

• ECOG status greater than 2
• Previously received IVC within 6 months prior to randomization
• Biochemical deficiency in G6PD
• Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min
• Currently taking insulin or warfarin
• History of severe renal dysfunction or hemochromatosis
• Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization
• If pregnant or planning to become pregnant: not a carrier of the gene for G6PD deficiency
• Currently taking an investigational product or participation in an investigational study within the past 30 days
• Any reason which, under the discretion of the Principal Investigator or delegate, would preclude the patient from participating

Where it is running

• The Ottawa Hospital — Ottawa, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.